Depomed gets US rights to Janssen's Nucynta for $1.05bn
Executive Summary
Janssen Pharmaceuticals Inc. sold Depomed Inc. the US rights to the pain therapy Nucynta (tapentadol) franchise for $1.05bn in cash.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice